SMC endorses Alexion’s Ultomiris
11th May 2021
The Scottish Medicines Consortium (SMC) has accepted a treatment for an ultra-rare disease that can cause progressive injury to vital organs via damage to the walls of blood vessels and blood clots in its May decisions.
Restricted use of Alexion’s Ultomiris (ravulizumab) has been recommended by the SMC, for the treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS).
Patients in Scotland who are complement inhibitor treatment-naïve or have previously received Alexion’s Soliris (eculizumab) for at least three months, and who have evidence of response to Soliris, are now eligible for the new treatment.
Alexion shareholders to get £86.95 of equity per share.
AstraZeneca to launch an enhanced version of Alexion’s Soliris.
AstraZeneca plc (LON: AZN) said on Saturday that it will buy Alexion Pharmaceuticals (NASDAQ: ALXN) for £29.50 billion. The acquisition marks the largest for the British pharmaceutical giant in history. As per AstraZeneca, bringing the U.S. drug manufacturer under its umbrella will help diversify its portfolio and expand its footprint in rare-disease and immunology drugs.
On the weekly chart, Alexion’s stock closed roughly 1% up on Friday. The Boston-based company is more than 10% up year to date in the stock market. At the time of writing, it has a market capitalisation of £20 billion and a price to earnings ratio of 28.33.
AstraZeneca to buy Boston biotech Alexion for $39 billion in rare-disease push
By John Lauerman Bloomberg,Updated December 12, 2020, 10:01 a.m.
Email to a Friend
AstraZeneca s facilities in Sodertalje, Sweden. The company agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares on Dec. 12, 2020.Mikael Sjoberg/Bloomberg
(Bloomberg) AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in treatments for rare diseases and immunology to its portfolio of medications for cancer and other illnesses.
The offer values Alexion at $175 a share, a 45 percent premium to the closing price on Friday. It would be the largest deal for AstraZeneca since it was founded in a combination of British and Swedish drugmakers in 1999.
Astrazeneca compra la farmacéutica estadounidense Alexion por 32 000 millones de euros elpais.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elpais.com Daily Mail and Mail on Sunday newspapers.